Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, HC Wainwright Analyst Says

Stoke Therapeutics (NASDAQ:STOK) had its price target lifted by HC Wainwright from $35.00 to $50.00 in a note issued to investors on Monday, MarketBeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 48.77% from the company’s previous close.

Several other equities analysts have also recently commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Stoke Therapeutics in a research report on Monday, December 8th. Wedbush increased their price objective on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Needham & Company LLC lifted their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, October 10th. Finally, Canaccord Genuity Group upped their target price on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $34.78.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $33.61 on Monday. The stock’s 50-day simple moving average is $30.10 and its 200 day simple moving average is $21.13. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of 50.16 and a beta of 1.14. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The company had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. On average, research analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 42,461 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $25.09, for a total transaction of $1,065,346.49. Following the transaction, the director directly owned 49,124 shares in the company, valued at approximately $1,232,521.16. This represents a 46.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Adrian R. Krainer sold 40,472 shares of the firm’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $26.98, for a total value of $1,091,934.56. Following the transaction, the director directly owned 364,246 shares in the company, valued at approximately $9,827,357.08. This represents a 10.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 182,166 shares of company stock worth $5,136,957 in the last three months. Insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Generali Investments Management Co LLC bought a new stake in shares of Stoke Therapeutics in the 3rd quarter worth approximately $41,000. BNP Paribas Financial Markets raised its position in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the period. Tower Research Capital LLC TRC lifted its stake in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the last quarter. AlphaQuest LLC purchased a new stake in Stoke Therapeutics during the first quarter valued at about $72,000. Finally, US Bancorp DE boosted its position in Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after buying an additional 11,108 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.